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ABSTRACT 
Plastic boxes with individual compartments are often used to improve 
medication compliance and only a few studies have been done on the 
stability of the tablet halves after placing them on these devices. In this 
investigation, wholes and halves tablets of furosemide, 
hydrochlorothiazide, spironolactone, warfarin sodium and atenolol and 
levothyroxine sodium were re-packaged and storing for sixty days 
under normal environmental conditions. The physical characteristics 
were observed and the quality attributes were verified. There were no 
changes in physical characteristics of all products. All products, except 
halves tablets of atenolol, showed accuracy according the test of 
uniformity of mass. The comparisons of dissolution profiles between 
whole tablets and tablets halves were adequate for hydrochlorothiazide and atenolol, but not 
for formulations of furosemide, spironolactone and warfarin sodium. Levothyroxine sodium 
showed a different dissolution behavior than expected. Whole tablets of atenolol do not meet 
specifications for uniformity of contents, neither the halves tablets of atenolol and 
spironolactone. According to the results, it is possible to re-package wholes tablets of 
furosemide, hydrochlorothiazide, spironolactone and warfarin sodium; but it is not advisable 
to maintain this practice for whole tablets of atenolol and levothyroxine sodium, neither for 
the halves of the rest of the products, except hydrochlorothiazide. These findings may 
become opportunities for improvement for pharmaceutical laboratories, as well as become a 
study topic for practitioners to advise the use of multi-compartment compliance aids, finally, 
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these results should not be extrapolated to drugs, manufacturers, lots and conditions other 
than those used in this study. 
 
KEYWORDS: Repackaging, drug stability, quality assurance, multicompartment 
compliance aids. 
 
INTRODUCTION 
Certain people should follow an appropriate therapeutic regimen, as part their therapy to treat 
the chronic pathologies that afflict them; however, as time passes they shows a tendency to 
decrease the compliance.
[1-3]
 
 
The treatment adherence concept is very broad due to it encompasses behaviors, as lifestyles 
from the patients regarding to compliance all the recommendations given by the prescriber 
who play an important role in the adherence achieving, which includes not only 
pharmacological therapy, especially in complex diseases such as the diabetes mellitus.
[4]
 
 
In this context, within the services or pharmaceutical practices in which information is 
provided to people, it is recommended the incorporation of routines that allow the systematic 
taking of the medication.
[5]
 since it has been detected that forgetfulness is a frequent cause of 
error to achieve a successful therapy. 
 
For example, the similarity in the form and color of medications taken by older people causes 
complaints and confusion, which is aggravated when they live alone or have physical 
limitations, impairment of cognitive function, comorbidities or are polymedicated persons. 
Therefore, the accompaniment and the development of specific strategies for them can mean 
an improvement in their life quality.
[6,7]
 
 
A strategy to improve the evolution of pharmacological therapy in patients from older 
populations and that is also applicable in children under twelve is to include family 
caregivers and caregivers in the activities to be developed.
[8]
 
 
Adherence to treatment in chronic conditions is complex, generally will be for life and often 
causes fatigue and restlessness. Therefore reinforcements are required to establish habits that 
remain in the time.
[9]
 Forgetting to take medications is a common problem that tends to 
improve with mnemonic help, such as the use of portable plastic boxes that contain several 
compartments identified with the schedules and the respective intake days of intake.
[10]
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These devices are designed with a certain number of compartments, which is variable; 
usually they are manufactured with 7 or 28 spaces
[11]
 or with another presentation type
[12]
 and 
can be purchased in multiple shopping centers. There is also the traditional pill box of a 
single compartment, which is recommended for short trips. Despite the increasing use of 
these in outpatients, little is known about changes in physical attributes, quality, and drug 
stability that may develop if the pharmaceutical formulations are removed from their original 
container and packaged again in a different container such as the plastic boxes with 
compartments. 
 
In order to establish habits to achieve a successful adherence to the pharmacological 
treatment of patients, caregivers must be integrated into the health team. The nurses and 
people are in charge of medication management sometimes do not have much knowledge 
about medicines or the care that must be taken during their administration, which is vital in 
nursing homes. 
 
In the treatment of acute short-term illnesses, lack of adherence rarely occurs, unless adverse 
effects appear or if there are other reasons, while in hospitals, inpatients generally receive 
medications for chronic medical conditions and adherence to therapy is critical to improving 
their diseases. The organization in health services must facilitate the dispensation and to 
improve the medicines distribution. In some pharmacies it is common to transfer the 
medicines from the original container to another temporary package (in blister or sachet)
[13]
 
that are placed in portables furniture drawers
[14]
 and they are distributed daily to the various 
services through a system with separate doses per hospitalized patient, known as unit dose 
system. In this way, every day the treatment is updated and the necessary adjustments are 
made according to the medical prescription. 
 
In some countries, such as Australia, dose administration aid (DAA) are is as an aid for drug 
administration, as it provides the patient the possibility of controlling the medication during a 
day or a week. Blisters or sachets containing various medicines may be placed in a 
compartment of the DAA (multi-dose pack) or only one product by compartment (unit-dose 
pack).
[15]
 In other latitudes, this system is offered not only to inpatients, but also to 
outpatients. The United States Pharmacopoeia (USP) 40th edition, in the general chapter 
<661> about packaging
[16]
 have regulations for these devices. 
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Along with the above, another professional practice allows the manipulation of some 
medicines by the nursing staff due to aspects related to drug stability. In these cases, the 
pharmacy service does not deliver the medication prepared and ready to administer by nurses. 
The lack of unification about the criteria regarding the preparation of the medicines make by 
the nursing service, sometimes led to inaccuracy in doses administered. The preparation, 
stability and compatibility of medicines are very sensitive issues that are indispensables to 
know in order to prepare the appropriate doses according needs of sick persons, especially in 
children.
[17]
 
 
In addition, physical alteration of a pharmaceutical form, such as breaking a tablet into 
fractions, spraying the tablets
[18]
 or adding the powder of a capsule to liquid or solid foods 
may modify the bioavailability of some medicaments.
[17]
 
 
In that regard, and to meet those needs, it exist a guide that recommends techniques to obtain 
the prescribed dosage with the required accuracy, thanks to the project Manipulation of 
Medicines Required in Children (MODRIC) of the United Kingdom.
[19]
 
 
Another problem to be considered is the professional acts regulation, arguing that the 
manipulation of pharmaceutical forms may have legal and ethical consequences.
[20]
 
 
However, professional practice contemplates that the therapeutic decision-making of 
marketed drugs is also presumably assumed by the prescriber
[21]
 who bases his expert 
judgment on the best available evidence, clinical experience, references of scientific articles 
and the risk-benefit balance, to obtain the guidelines to be followed in an individual patient 
therapy.
[22]
 
 
The official agency, which regulates medicines in different countries, determines whether the 
marketing authorization of the products is given, such authorization is specific to indications, 
doses and population. 
 
In frequently practice, it is possible to use the authorized medicinal product that is marketed, 
but changing the indication, potency, pharmaceutical form, age and the administration route. 
These doses are outside the manufacturer's labeling (off-label), for example the use of tablets 
halves or the drug repackaging in a container other than the original one. 
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When repackaging pharmaceutical formulations, the preparer is responsible for ensuring 
product quality during storage and shipment, in addition, the maximum dates for its possible 
use should be taken into account, based on considerations of the active principle, 
pharmaceutical formulation and route of administration, among others.
[23]
 
 
As repackaging a medicinal product, any changes in stability should be assessed, so that the 
original expiration date reported by the manufacturer will be valid if the storage provides the 
same conditions specified by the pharmaceutical laboratory on the label.
[16]
 
 
The original packaging preserves the product integrity and in this context, the World Health 
Organization (WHO) in 2002 issued a guide for the packaging of pharmaceutical products,
[25]
 
which mentions the influence of variations in humidity, light, oxygen, temperature and 
biological contamination. This guide also identifies damages that may occur due to the 
inefficiency of the packaging, such as: physical damage, chemical reactions and absorption of 
undesirable substances. 
 
The USP 40 provides a guidance for conducting stability studies and establishing the 
expiration date of solid formulations by assessing physical signs of common deterioration 
and aspects not perceived with the naked eye such as degradation and chemical reactions that 
could lead to losses in the active pharmaceutical ingredients concentration.
[16]
 
 
If are not specified storage conditions on the label of the new packaging, storage in a 
controlled ambient temperature is recommended and avoid places with excessive or variable 
conditions of heat, cold or light, such as heating or fluorescent lighting.
[16]
 
 
Other entities linked to the medicines quality, such as the International Conference on 
Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human 
Use: ICH (Q1A-Q1F),
[26]
 the European Medicines Agency (EMA)[27] and the WHO
[28]
 
issued directives similar to those cited by USP 40. 
 
In Costa Rica there is current legislation on medicinal products stability studies of for human 
use that must be performed with the control of variables such as temperature, humidity and, if 
necessary, light.
[29]
 
 
Stability studies carried out to obtain scientific evidence of the permanence of quality 
characteristics in pharmaceutical products throughout their useful life and the packaging type 
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that protects them from external factors influences pharmaceutical formulations. When re-
packaging a drug, it is necessary to consider that the new packaging must guarantee stability 
until it is apply or consumed by the patient.
[24]
 
 
The medicines re-packaged in customized packages are regulated by the USP 40 general 
chapter <661> about containers, which establishes an use no longer than 60 days from its 
preparation.
[16]
 
 
With respect to solid pharmaceutical formulations, they have the advantage that the 
medicament tends to decompose less than in a liquid formulation. In general, very stringent 
conditions for the tablets storage, such as temperatures below 15 degrees or 30% relative 
humidity, are not required; therefore the manufacturer must indicate on the product label the 
recommended storage conditions and the expiration date. When the pharmaceutical form of 
the tablets that are commercially available at the market, are extracted from their original 
packaging and placed in another reservoir, the manufacturer cannot assure the guarantee 
about the validity. In this sense, the person in charge of the repackaging is responsible for the 
maintenance of medicine qualities the during the storage in the determined environmental 
conditions that are established; these and other considerations must be adhered to by the 
United States Food and Drug Administration (FDA).
[30] 
 
In Costa Rica, there are two climatic seasons a year, one dry and one rainy, so that in each 
season there are atmospheric changes. A drug storage study depended of these changes and 
the results cannot be extrapolated to other latitudes, even within the country itself. This 
investigation taken place in San Pedro de Montes de Oca from December 2014 to November 
2015, under an annual 21±1
o
C (Celsius degree) temperature
[31]
 and a 55±10% relative 
humidity percentage in the dry season (December-April) and 70±10% the rest of the year 
(May-November).
[32]
 These is a subtropical zone according to the ICH classification (25 oC 
to 60% of relative humidity).
[20]
 
 
Hence, this study aim was to evaluate the doses accuracy and the quality attributes, of wholes 
and halves tablets, of furosemide, hydrochlorothiazide, spironolactone, warfarin sodium, 
atenolol and levothyroxine sodium, re-packaged in individual plastic compartments for sixty 
days. These drugs were selected because they are used for the pharmacological treatment of 
high relevance pathologies in Costa Rica. 
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Rather, the study established the usual storage conditions that would be assumed by patients 
using individual plastic compartments to improve therapeutic compliance. During the 
bibliographic research, no study was found carried out in Costa Rica under these conditions. 
It is important to clarify that this study did not intend to obtain results that solve aspects 
related to accelerated stability tests, a long time, intermediate or under conditions of forced 
degradation; neither the consequences of improper storage of re-packaged drugs were not 
assessed; nor was it known whether the tablets halves met all requirements that are requested 
by the FDA from manufacturers of functional (and non-decorative) scored tablets. 
 
MATERIALS AND METHODS 
Materials 
Small multi-dose bottle with 100 tablets for warfarin sodium 5 mg and blister packs of 10 
individual units for furosemide 40 mg tablets, hydrochlorothiazide 25 mg, spironolactone 100 
mg, atenolol 50 mg and levothyroxine sodium 100 μg whose trade names mark remain 
anonymous for confidentiality matters. Their acquisition was made in Private Assistance 
Pharmacies of San José, Costa Rica. 
 
The plastic boxes with 7 or 28 individual compartments, obtained in the national market, for 
convenience. 
 
The following calibrated analytical equipment was used: 
 
Analytical balance (Accurate LS 120A ± 0.0001g, Switzerland). 
 
UV-VIS Spectrophotometer (Thermo Scientific Orion AquaMate 8000 UV-VIS 
Spectrophotometer, China). 
 
High Performance Liquid Chromatograph HPLC (Perkin Elmer Flexar series 200; USA). 
 
Disolutor paddle or apparatus 2 (Varian VK7010; USA) with six vessels. 
 
Methods 
The methodology is presented according to the order of these activities. 
1. Repacking of products the first day and preparation for conduct the quality tests on days 
7, 14, 30 and 60 from the start day. 
2. Analytical procedures and validation. 
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3. Quality tests: no changes in physical characteristics of products, tests of uniformity of 
weight (mass), dissolution profiles and content uniformity. 
 
Repacking of products 
The activities developed the starting day were the following: 
Fifty whole tablets of each medicament were weighed individually and the masses were 
scored. They were placed in the assigned compartment. 
 
Twenty-five tablets of each medicament were removed from their original container and were 
weighed individually. Each tablet was divided in halves and each fragment weighted was 
placed in the compartment codified corresponding which containing a whole tablet. The 
masses of the whole tablet and the two halves were scored. 
 
Forty compartments per product were stored in a shelf located in a cool, dry place away from 
direct sunlight at room temperature. After 7, 15, 30 and 60 day, the content of ten 
compartments was evaluated. 
 
Analytical procedures and validation 
The procedure indicated by BP, 2013 in the case of warfarin sodium was varied since a 
complete validation was performed. 
 
The tablets of furosemide, hydrochlorothiazide, spironolactone, atenolol were analyzed 
according to the official British Pharmacopoeia BP, 2013 (BP, 2013)
[35]
 methods and the 
procedure for levothyroxine sodium was official in USP 40 using an HPLC-UV technique.
[16]
 
 
The validation of official procedures was partial according to the "Verification of 
Compendial Procedures", general chapter <1226> of USP 40.
[16]
 
 
The validations were verified in terms of specificity, precision, accuracy, linearity and 
linearity range. Those validation were performed according to the recommendations of 
ICH.
[26]
 The specificity was demonstrated using one of the following two procedures: 
 
a. The comparison of the slopes of the calibration curves and the added dose. 
b. The overlap of the absorption spectra of the reference substances and the tablets after 
applying the test procedure. 
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Precision and intra-day and inter-day accuracy was evaluated with six replicate samples at 
low, medium and high concentrations of the calibration curve. The Association of Official 
Analytical Chemicals (AOAC) considers accuracy in the concentrations of 10 mg/L when 
DSR% <6% and ± 115% recovery.
[16]
 
 
Linearity and range were established according to expected concentrations in the dissolution 
profiles of whole tablets and halves. 
 
The linear adjustment, the intercept with a statistical value equal to zero and the coefficient of 
determination higher than 0,995 were verified. 
 
Quality tests 
Physical characteristics 
Color, odor, presence of spots or agglomeration were observed in 10 units at baseline, 7, 15, 
30 and 60 days. 
 
Uniformity of weight (mass) Appendices XII C1, BP 2013 The pharmacopeical methodology 
established this test for 30 tablets. 
 
Because for the storage study a group of 10 units is to be evaluated at any time, the test was 
modified as follows. 
 
Weighed individually 10 units and determined the average mass. For uncovered or film 
coated tablets, no more than 1 individual mass was deviated from the average mass by more 
than the percentages showed in Table 1 and none deviated by more than twice that 
percentage. 
 
Table 1: Permissible percentage of maximum deviation in mass uniformity 
Average mass BP 
2013 
Deviation 
(%) 
80 mg or less 10 
81 to 249 mg 7,5 
250 mg or more 5 
 
The average mass of unbroken tablets was obtained from the 50 units weighed on the start 
day and the percentage of deviation of a whole tablet at each storage time was established by 
the formula: (individual mass-average mass)*100/average mass. 
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Because the tablets halves have significant variability with each other, to calculate the 
percent deviation in half, this formula was used: (mass obtained on the start day-mass on the 
day of the test)*100/average mass of 50 tablets halves weighted the start day. 
 
Dissolution profiles 
The methodologies were based on dissolution tests of pharmacopoeial monographs, but using 
various sampling times and a calibration curve. For drugs, a stirring speed of 50 o 75 r/min 
was selected in apparatus 2, according to the specification of the monograph used. The 
temperature of dissolution medium was 37±5 Celcius degree. Other experimental conditions 
are shown in Table 2. 
 
Table 2: Experimental conditions tests applied to the dissolution profiles for each drug. 
Drugs in tablets 
Dissolution medium and 
volume (mL) 
Sampling times 
(minutes) 
Furosemide 40 mg 
Phosphate buffer pH 5,8 
(900) 
5, 10, 15, 20, 30, 45, 60 
Hydrochlorothiazide 25 mg HCl 0,1M (500) 5, 10, 15, 20, 30, 60, 90 
Spironolactone 100 mg 
HCl 0,1M with sodium 
laurylsulphate 0,1 % (1000) 
5, 10, 15, 20, 30, 60, 90 
Warfarin sodium 5 mg 
Phosphate buffer pH 6,8 
(900) 
5, 10, 15, 20, 30, 45, 60 
Atenolol 50 mg 
Acetate buffer 0,1M pH 4,6 
(500) 
5, 10, 15, 20, 30, 45, 60 
Levothyroxine sodium 100 µg HCl 0,1M (500) 5, 10, 15, 20, 30, 45, 60 
 
In the six-vessel apparatus, three whole tablets and three halves of tablets were placed 
randomly. Twelve whole tablets and twelve tablets halves were analyzed for each drug. As a 
reference, the Q value was set at 70% to 45 minutes, as indicated in BP 2013.
[35]
 
 
Uniformity of dosage units Appendices XII C4, BP 2013 
The uniformity of content or mass variation assays may be applied to demonstrate uniformity 
of dosage units, according to the dose and proportion of active ingredient (% of mass) in the 
formulation. 
 
The dose and proportion of active ingredient (% mass) are two parameters that define the 
assay to evaluate the uniformity of the dosage units. 
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For tablets with a content ≥ 25 mg and a mass percentage ≥ 25%, the mass variation test was 
applied. The uniformity of the contents can be used in tablets with a drug content <25 mg or a 
mass percentage <25%. However, this second test could be applied in all cases. 
 
The table 3 shows the corresponding test applied in the study tablets. The abbreviation CU 
refers to the test of uniformity of content and MV to the test of variation of mass. 
 
Table 3: Application of content uniformity (CU) and mass variation tests for study 
tablets. 
Active pharmaceutical 
ingredient 
Drug dose per 
whole tablet (mg) 
Percentage of content 
(% of mass) 
Methodology to 
apply 
Furosemide 40 24 CU 
Hydrochlorothiazide 25 13 CU 
Spironolactone 100 18 MV 
Warfarin sodium 5 2 CU 
Atenolol 50 25 MV 
Levothyroxine sodium 0,1 0 CU 
 
In the uniformity of content, the 10 individual units corresponding to the day of storage were 
analyzed to determine the individual labeling percentage. 
 
The mass variation test was applied to 10 units. The labeling percentage of each individual 
unit was obtained by the ratio between the test labeling percentage of tablet samples, the 
mean mass and the individual mass. 
 
Regardless of the test used, the result was expressed in terms of acceptance value (AV) 
The formula of AV included the follow terms: 
X = average of individual labeling percentages 
k = 2, 4 
 
s = standard deviation 
T = 100 
 
M = Reference value having different values depending on the case: 
 M = 0 if 98, 5 < X < 101,5  
 M = 101,5 if X > 101,5  
 M = 98,5 if X < 98,5 
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The formula for calculating AV was: 
VA =  M - X  + k * s 
 
Specification in the uniformity of dosage units: AV ≤ 15, 0. 
 
RESULTS AND DISCUSSION 
Analytical procedures and validation 
 
The data of the tests applied to demonstrate the appropriateness of the procedures are showed 
in the table 4. 
 
Table 4: Verification of validation parameters of analytical procedures referring to 
specificity, precision and accuracy (intra-day and inter-day), linearity and range. 
Specificity 
Precision and 
accuracy (intraday, 
inter-day) 
Linearity and range 
Furosemide 
 
There is no significant difference 
between the slope of both calibration 
curves: (P> 0.05) y (critical t> 
experimental t) 
Inter-day 
DSR< 3,6 % 
ER % -4,6 to 5,0 % 
 
 
 
 
 
 
 
 
 
 
r > 0,995 
Intercept statistically equal 
to zero 
Lack of significant deviation 
with respect to linear 
Regression. 
Range: 2 - 14 mg/L 
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Specificity 
Precision and 
accuracy 
(intraday, 
inter-day) 
Linearity and range 
Hydrochorotiazide 
 
There is no significant difference 
between the slope of both calibration 
curves: (P> 0.05) y (critical t> 
experimental t) 
Intraday 
DSR< 3,5 % 
ER % -6,6 to 2,8 
% 
Inter-day 
DSR< 2,8 % 
ER % -4 to 4 % 
 
r > 0,995 
Intercept statistically equal 
to zero 
Lack of significant deviation 
with respect to linear 
Regression. 
Range: 4 - 16 mg/L 
 
Specificity Precision and 
accuracy 
(intraday, 
inter-day) 
Linearity and range 
Spironolactone 
 
There is overlap between the absorption 
spectra of the spironolactone standard 
and 
Tablet solutions (8 mg/L). 
Intraday 
DSR< 1,5 
% 
ER % -2 
to 4 % 
Inter-day 
DSR< 4,5 
% 
ER % -1,2 
to 5,3 % 
 
 r > 0,995 
Intercept statistically equal to 
zero 
Lack of significant deviation 
With respect to linear 
regression. 
Range: 3 - 10 mg/L 
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Specificity Precision and 
accuracy 
(intraday, 
inter-day) 
Linearity and range 
Warfarin sodium 
 
There is overlap between the absorption 
spectra of the warfarin sodium standard 
and 
The tablet solutions. 
Intraday 
DSR< 1 % 
ER % 0,3 
to 1 % 
Inter-day 
DSR< 2 % 
ER % -0,6 
to 1,3 % 
  
r > 0,995 
Intercept statistically equal to 
zero 
Lack of significant deviation 
With respect to linear 
regression. 
Range: 0,4 – 2,5 mg/L 
 
Specificity Precision and 
accuracy 
(intraday, 
inter-day) 
Linearity and range 
Atenolol 
 
There is no significant difference between 
the 
slope of both calibration curves: (P> 0.05) y 
(critical t> experimental t) 
Intraday 
DSR< 1 
% 
ER % 
-0,65 to 
3 % 
Inter-day 
DSR< 
5,2 % 
ER % 
-10 to 6 
% 
 
r > 0,995 
Intercept statistically equal 
to zero 
Lack of significant deviation 
with respect to linear 
regression. 
Range: 20 - 75 mg/L 
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Specificity Precision and 
accuracy 
(intraday, 
inter-day) 
Linearity and range 
Levothyroxine sodium 
 
The chromatogram of the test of related 
substances 
applied to tablets of levothyroxine sodium 
showed 
the separation of the chromatographic peak 
assigned to this active principle and the 
different 
Retention times of the other substances. 
Intraday 
DSR< 
1,3 % 
ER % 
-1,61 to 
1,38 % 
Only a concentration 
of 7,75 
mg/L was utilized 
Table 
 
Table 4 presented that the results of procedures validations had values suitable for their use 
according to the indications of ICH
[26]
 and AOAC
[36]
 in the ranges of concentrations used for 
all products. 
 
The specificity of the analytical procedures for the tablets was demonstrated by statistically 
comparing the slopes of the curves of the added doses and the calibration curves or by 
superposition of the absorption spectra. 
 
The results, with DSR<6% and ±15% relative error, demonstrated the accuracy and the 
precision in both conditions selected.
[16] 
 
The linear adjustment, the intercept with a statistical value equal to zero and the coefficient of 
determination higher than 0.995 were verified for all analytical procedures.
[26]
 
 
Physical characteristics 
Table 5 provides a summary of the characteristics of the tablets (wholes and halves). 
Negative signs indicate absence of changes during observations. 
www.wjpr.net                                 Vol 6, Issue 10, 2017.                                                          
 
 
77 
 
Baudrit et al.                                                         World Journal of Pharmaceutical Research 
Table 5: Physical characterization of tablets (whole and halves) of the drugs under 
study 
 
 
The results indicated that in the intact tablets or in halves, regardless of drug, no change in 
color, odor, presence of spots or agglomeration were observed throughout the storage. 
 
However, Pinderfields General Hospital detailed a list of repackaged drugs in multi-
compartment compliance aids
[37]
 indicating changes in furosemide tablets that should be 
monitored. And Church and Smith point out that manufacturers discourage repackaging of 
furosemide, in plastic boxes with individual compartments, for lack of stability studies.
[39]
 
 
Uniformity of weight (mass) 
The initial mass of whole tablets and halves was obtained and associated in accordance with 
the test specification. These results are shown in Table 6. 
 
Table 6: Maximum mass deviation (%) assigned with respect to the average mass of 
products. 
 
Average mass of ten 
whole tablets (g) 
Deviation (%) for the 
whole tablet 
Deviation (%) for 
half tablet 
Furosemide 0,1691 7,5 10 
Hydrochlorothiazide 0,1992 7,5 7,5 
Spironolactone 0,5645 5 5 
Warfarin sodium 0,2268 7,5 7,5 
Atenolol 0,1993 7,5 7,5 
Levothyroxine sodium 0,1021 7,5 10 
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The most common deviation is 7,5% because the tablets had a similar weight. The results of 
the uniformity of mass for all products are summarized in table 7. The positive sign indicates 
compliance with the specifications and the negative the non-compliance, followed by the 
number of units deviated, in parentheses, if applicable. 
 
Table 7: Results of mass uniformity test at storage times according to specifications. 
 Whole tablets Halves of tablets 
Days of analysis during storage 7 14 30 60 7 14 30 60 
Furosemide + + + + + + + + 
Hydrochlorothiazide + + + + + + + + 
Spironolactone + + + + + + + + 
Warfarin sodium + + + + + + + + 
Atenolol + + + + + + - (2) - (2) 
Levothyroxine sodium + + + + + + + + 
 
According to Table 7, five drugs meet the specifications for whole tablets and their halves. 
Atenolol showed the same condition for whole tablets, however, the halves tablets of this 
drug did not meet the test approval criteria, since there were two units that deviated from the 
specification at 30 and 60 days, their values exceeded twice the maximum allowed value. 
 
Dissolution profiles 
The superposition of dissolution profiles of whole tablets and halves is shown in Figure 1, for 
each drug: (a) furosemide, (b) hydrochlorothiazide, (c) spironolactone, (d) warfarin sodium, 
(e) Atenolol. Figure 2 shows only the dissolution profile of the wholes tablets of 
levothyroxine sodium. 
 
 
(a) (b) 
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(c)                                                           (d) 
 
 
(e) 
Figure 1: Overlap of dissolution profiles for whole halves and tablets of (a) furosemide, 
(b) hydrochlorothiazide, (c) spironolactone, (d) warfarin sodium and (e) atenolol. 
 
In the Figure 1, for all products, the dissolution profiles of whole tablets had shapes 
illustrating formulations with immediate drug release. 
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In addition, it is not advisable to repackaging of spironolactone (c), furosemide (a) and 
warfarin sodium (d) tablet halves in view of the observed difference in the drug release as 
compared to the whole tablets, although at 45 minutes the units of the three drugs mentioned 
reach 75% dissolved, with the exception of warfarin sodium. 
 
Although the dissolution profiles are in vitro tests, the behavior of the drug under in vivo 
conditions is not known with certainty. However, it may be suspected that the behavior of the 
furosemide moiety of tablets could have a different blood velocity and blood concentration, 
as evidenced by Zafar et al.
[39]
 in a study of crushed tablets of clopidrogel administered via 
nasogastric tube with faster and greater absorption than that of whole tablets by mouth. 
 
An investigation performed at Pharmacy Department of Pinderfields General Hospital, 
mentioned that the re-packaging of whole tablets of spironolactone, furosemide, and warfarin 
sodium was discouraged, although stability studies were not reported.
[37] 
 
Atenolol (Figure 1 e) showed adequate overlap of dissolution profiles of whole tablets and 
tablet halves. 
 
Figure 2: Dissolution profile of the wholes tablets of levothyroxine sodium. 
 
For levothyroxine sodium (Figure 2), data were only obtained for whole tablets, since the 
detection limit of the HPLC procedure was not sensitive enough to quantify the drug in the 
dissolution test of the tablet halves. 
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The dissolution profile of whole tablets of levothyroxine sodium did not show a plateau 
response, unlike the other products analyzed, and the maximum dissolved percentage of each 
individual unit did not reach 75% to 45 minutes. 
 
Uniformity of dosage units 
The numerical data in Table 8 reflect the results of the tests applied to all dosage units, 
expressed as acceptance values. 
 
Table 8: Acceptance values for all the products studied in the uniformity of the dosage 
units. 
 Whole tablets Halves of tablets 
Products 
Starting 
day 
7 14 30 60 
Starting 
day 
7 14 30 60 
Furosemide 2,5 9,4 11,1 5,0 7,3 4,1 7,6 7,9 3,1 11,3 
Hydrochlorothiazide 4,8 5,2 7,5 11,8 3,5 7,7 2,8 2,9 10,0 2,4 
Spironolactone 11,2 3,0 15,2 2,7 4,0 3,0 4,5 5,2 6,6 7,8 
Warfarin sodium 6,6 8,2 2,5 4,5 14,7 3,3 3,0 2,8 2,2 3,1 
Atenolol 28,5 26,7 4,0 10,0 3,0 38,7 40,9 19,5 15,9 8,3 
Levothyroxine sodium 3,5 3,5 3,0 4,5 5,6 5,6 3,9 3,6 3,3 3,7 
 
The halves of tablets of atenolol had values of acceptance greater than 15, 0 during the 60 
days of storage, reason why the specifications are not fulfilled. In addition, the results at 
baseline and day 7 for whole tablets of atenolol had the same situation. 
 
In view of this situation, on the first day, it was decided to perform dissolution profiles with 
six units of whole tablets and six halves tablets of atenolol, in order to complete the quality 
tests for this product. 
 
Regardless of the case of atenolol, Table 8 shows that all acceptance values are less than 15, 
except for the whole tablets of spironolactone 100 mg on day 14, which presented a result of 
15.2. 
 
Although almost all drugs presented adequate acceptance values at all storage times. 
 
In order to visualize if there is any tendency towards increasing or decreasing the amount of 
drug in the dosage units over time, the confidence intervals were elaborated. 
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The results obtained should not be confused with those of the assay of drug content of the 
tablets where the analyzed samples are portions of tablets sprayed and not ten samples of 
individual units. 
 
The analysis of the confidence intervals of the percentages of labeling per group of 10 tablets 
analyzed, visualized some tendencies regarding the behavior of results during the storage. 
The confidence intervals of the labeling percentage of each group of 10 units were calculated 
and can be seen in Figures 3 to 8. 
 
 
(a) (b) 
Figure 3: Confidence intervals of the percentages of labeling per day of storing of (a) 
whole tablets and (b) halves tablets of furosemide. 
 
At all storage times, the whole furosemide tablets show values between 90,0 and 110,0% as 
shown in Figure 3 (a). For the tablets halves, an offset was found at 60 days, since that 
interval has values higher than 110, 0%. 
 
Khan in a furosemide stability study in original packaging and re-packaged (both blister 
packs) was developed for a long-term year and also under conditions of accelerated 
stability.
[40]
 It was found that for whole tablets of furosemide 40 mg the quality attributes 
were not affected by any of the conditions established. 
 
In our study, a similar condition was observed in terms of the results of the furosemide 
content per tablet, up to two months, but with different environmental characteristics. 
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(a) (b) 
Figure 4: Confidence intervals of the percentages of labeling per day of storing of (a) 
whole tablets and (b) halves tablets of hydrochlorothiazide. 
 
Figure 4 concerning hydrochlorothiazide showed that at all times the confidence intervals 
were between 90, 0 and 110,0% of the labeling for whole tablets and halves. 
 
(a) (b) 
Figure 5: Confidence intervals of spironolactone labeling percentages per day of storage 
of (a) whole tablets and (b) halves. 
 
Figure 5 showed for whole spironolactone tablets values between 90,0 and 110,0% at all 
confidence intervals. However, tablet halves tend to decrease their content as the storage time 
elapses, with values below 90,0% of the labeling at 30 and 60 minutes. 
 
In an investigation, Margiocco et al evaluated the uniformity of contents for spironolactone 
tablets. These fractions were re-packaged in plastic containers and stored for 30 days.
[41]
 
Their results showed a decrease in the content of active ingredients as time evolved perhaps 
due to chemical degradation. The results of our study presented a similar tendency for the 
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halves of the tablets, but for a longer period of 60 days and under different storage 
conditions. 
 
 
(a) (b) 
Figure 6: Confidence intervals of warfarin sodium labeling percentages per day of 
storage of (a) whole tablets and (b) halves. 
 
In the case of warfarin sodium in whole tablets and in halves, Figure 6 shows that for all 
confidence intervals the limits were found to be between 90,0 and 110,0 percent labeling but 
more accurate on halves tablets. 
 
 
(a) (b) 
Figure 7: Confidence intervals of the percentages of labeling per day of storing of (a) 
whole tablets and (b) halves tablets of atenolol. 
 
According to Figure 7, when storage time increases both whole atenolol tablets and halves, 
they tend to increase the percentage labeling values near 70% in the first two dates to a range 
of 90-110% on days later. 
 
For whole atenolol tablets, acceptance values of less than 15, 0 were obtained at 14, 30 and 
60 minutes, which coincide with the narrow confidence intervals at that time, shown in 
Figure 7 (a). 
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For the halves tablets of atenolol, the acceptance values were much higher than 15,0 at the 
first day, 7, 14 and 30 days as shown in Table 7, which indicates a high variability of the 
results, a situation can be explained in Figure 6 (b) when is observed wide intervals of 
confidence, at any moment analyzed. 
 
In view of obvious variations in drug content as storage time increased, the behavior of the 
release of atenolol was studied using dissolution profiles applied to six units of the two doses. 
Figure 8 presents the overlap of the dissolution profiles of the whole tablets and the halves of 
the tablets where the continuous lines correspond to the firsts and the lines with points to the 
seconds. 
 
 
Figure 8: Comparative dissolution profiles of whole tablets and halves of atenolol 
tablets during storage evaluated at baseline, 7, 14, 30, and 60 days. 
 
As shown in Figure 8, the whole tablets and tablet halves exhibited a very similar behavior 
between them at each evaluated moment. 
 
These findings show an adequate release of atenolol in the dissolution medium used during 
the 60 days of storage. But due to the low labeling rates found up to day 14 of storage, it 
seems necessary to establish a different quantitative method for analyzing the content of 
atenolol, particularly in the case of generic medicines, the results of which should coincided 
with the good performance of the products in the released in vitro. 
 
A laboratory manufacturer indicates that in the absence of stability studies, it is preferable not 
to re-pack atenolol tablets into plastic boxes with individual compartments.
[38]
 Given the 
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results obtained in our study, atenolol, which can be split in half and stored in plastic boxes 
with individual compartments. 
 
The final result on the uniformity of the dosage units corresponds to tablets of levothyroxine 
sodium. A comparison of the dissolution profiles of whole tablets and their halves is shown 
in Figure 9. 
 
 
(a)                                                                  (b) 
Figure 9: Confidence intervals of levothyroxine sodium labeling percentages per day of 
storage of (a) whole tablets and (b) halves. 
 
As shown in Figure 9 the adequate behavior of the whole tablets and their halves, have values 
between 90 and 100 percent of labeled levothyroxine sodium. 
 
CONCLUSIONS 
According to the results, it is possible to re-package wholes tablets of furosemide, 
hydrochlorothiazide, spironolactone and warfarin sodium; but it is not advisable to maintain 
this practice for whole tablets of atenolol or levothyroxine sodium, neither for the halves of 
the rest of the products, except hydrochlorothiazide. 
 
These findings may become opportunities for improvement for pharmaceutical laboratories, 
as well as become a study topic for practitioners to advise the use of multi-compartment 
compliance aids, finally, these results should not be extrapolated to drugs, manufacturers, lots 
and conditions other than those used in this study. 
 
It is recommended that the date of re-packaging of tablets in plastic boxes with individual 
compartments, the maximum date of use should be noted. 
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In general, the low dissolution of the tablets halves relative to the whole units should be 
analyzed by the manufacturing laboratories to verify the critical points of the production and 
the associated risks. 
 
In the case of treatments with 100 mg of levothyroxine sodium half-tablets, the patient should 
have greater medical support because of the possibility of a change in the way the drug is 
released in the specific studied formulation. 
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